Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025 Jun. 09, 2025 8:00 AM ET Anixa Biosciences, Inc. (ANIX) ...

--Anixa Biosciences, Inc., a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt ...

Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025 By Anixa Biosciences, Inc. Jun 9, 2025 Updated 10 hrs ago ...

In a twist no one expected, researchers found that many HV tumors express CA125, a marker known for its role in ovarian cancer. This means that 1 in 4 bladder cancer cases may be hiding this ...

Ditch these lifestyle habits that could be raising your ovarian cancer risk. (Image by Pexels) The average overall 5-year survival rates are approximately 48.6 per cent.

If you have ovarian cancer, there’s a good chance that at some point you’ll experience a complication — a problem or side effect of either the disease or treatment. (1) These complications ...

Primary surgery for advanced ovarian cancer significantly improves progression-free survival but not overall survival compared with neoadjuvant chemo and interval cytoreductive surgery.

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025 Provided by GlobeNewswire Jun 18, 2025, 5:05:00 AM ...

Obesity, a growing global epidemic, is identified as a significant, modifiable risk factor for ovarian cancer, a deadly gynecologic malignancy often diagnosed late. Research indicates that increased ...

Session ID: 2025-06-28:6adbb0cf66cf1dfca36b4b5e Player Element ID: Ve269e51d_e4d5_4feb_b17c_388708de9ffa_6374460531112 ...

This was the 15th run held in memory of Katie Oppo, a 19-year-old who died after battling a rare form of ovarian cancer called Small Cell Carcinoma of the Ovary-Hypercalcemic Type, or SCCOHT. Oppo ...

AbbVie's Elahere has been shown to reduce the risk of death in patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer by a third, reinforcing its blockbuster ...